- Tandem Diabetes Care Inc TNDM reported Q4 FY22 sales of $220.50 million, missing the consensus of $221.83 million.
- The automated insulin delivery technology maker posted adjusted losses of $(0.46) million, compared to an income of $10.81 million a year ago.
- Tandem also increased its worldwide installed base by 29% to approximately 420,000 customers this past year.
- Renewal pump shipments in the U.S. increased by approximately 60% compared to 2021.
- The company said it exited 2022 with a record growth rate in renewal pump shipments totaling 75% in the fourth quarter.
- Worldwide pump shipment fell 5.2% to $35.6 million.
- Adjusted gross margin fell to 53% from 54% a year ago. The company reported an adjusted operating income of $(2.39) million versus $12.74 million a year ago.
- Guidance: Tandem set its 2023 guidance for non-GAAP revenues of $885-$900 million, up 10%-12% Y/Y, compared to the consensus of $891.55 million.
- Price Action: TNDM shares closed 8.81% lower at $36.51 during after-hours trading on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in